{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:52:54Z","timestamp":1771462374425,"version":"3.50.1"},"reference-count":33,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1080\/13696998.2020.1840181","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T13:24:03Z","timestamp":1603286643000},"page":"1516-1524","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Early health economic modelling for a treatment candidate in hidradenitis suppurativa"],"prefix":"10.1080","volume":"23","author":[{"given":"Damon","family":"Willems","sequence":"first","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands"},{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mata","family":"Charokopou","sequence":"additional","affiliation":[{"name":"UCB Pharma, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1026-570X","authenticated-orcid":false,"given":"Silvia M. A. A.","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4274-9258","authenticated-orcid":false,"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2013-131994"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2000.00087.x"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15280"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2019.04.006"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.1950"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200683"},{"key":"CIT0009","unstructured":"National Institute for Health and Care Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa TA392. 2016."},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14976"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.2522"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17101"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04263.x"},{"key":"CIT0014","unstructured":"Van Wilder P, Mabilia V, Kuipers Cavaco Y, et\u00a0al. Towards a Harmonised EU Assessment of the Added Therapeutic Value of Medicines.Study of the ENVI Committee.2015. [cited 2019 Sep 13]. Available from: http:\/\/www.europarl.europa.eu\/RegData\/etudes\/STUD\/2015\/542219\/IPOL_STU(2015)542219_EN.pdf"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0509-1"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-81"},{"key":"CIT0017","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"Briggs A","year":"2006"},{"key":"CIT0018","unstructured":"National Institute for Clinical Excellence. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392). 2016. [cited 2019 Sep 13]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta392\/chapter\/4-Committee-discussion"},{"key":"CIT0019","unstructured":"Tappenden P, Carroll C, Stevens J, et\u00a0al. Adalimumab for treating moderate to severe hidradenitis suppurativa: a single technology appraisal. Addendum: Patient access scheme. University of Sheffield. 2016. [cited 2019 Sep 13]. Available from: https:\/\/www.nice.org.uk\/guidance\/TA392\/documents\/committee-papers"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17537"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.028"},{"key":"CIT0025","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal (PMG9). 2013. [cited 2019 Sep 13]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/introduction"},{"key":"CIT0026","unstructured":"Curtis L, Bruns A. Unit Cost of Health & Social Care 2019. Personal Social Services Research Unit, Kent Academic Repository. n.d. Available from:"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.3310\/hta19140"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"CIT0029","unstructured":"Pharmaceutical Benefits Advisory Committee: Adalimumab for the initial treatment of moderate-to-severe Hidradenitis Suppurativa (Public Summary document), March 2016. [cited 2019 Sep 13]. Available from: http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2016-03\/files\/adalimumab-psd-march-2016.docx"},{"key":"CIT0030","unstructured":"Pharmaceutical Benefits Advisory Committee: Adalimumab for the initial treatment of moderate-to-severe Hidradenitis Suppurativa (Public Summary document), July 2016. [cited 2019 Sep 13]. Available from: www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2016-07\/files\/adalimumab-psd-july-2016.docx"},{"key":"CIT0031","unstructured":"Pharmaceutical Benefits Advisory Committee: Adalimumab for initial treatment and Authority Required (Streamlined) listing for continuation of adalimumab for the treatment of moderate to severe hidradenitis suppurativa (HS) (Public Summary Document), November 2016. [cited 2019 Sep 13]. Available from: www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2016-11\/files\/adalimumab-psd-november-2016.docx"},{"key":"CIT0032","unstructured":"Canadian Agency for Drugs and Technologies in Health: Common Drug Review (CDR) Pharmacoeconomic review report for Humira, May 2016. [cited 2019 Sep 13]. Available from: https:\/\/cadth.ca\/sites\/default\/files\/cdr\/pharmacoeconomic\/SR0455_HumiraHS_PE_Report.pdf"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-017-0488-2"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2020.1840181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T05:56:05Z","timestamp":1723787765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2020.1840181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.1080\/13696998.2020.1840181"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2020.1840181","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-07","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}